Jeremy Klukan read the feedback correctly
musculoskeletal ultrasound for dynamic soft tissue evaluation, ligament laxity, tendinopathy, guided injections Evidence snapshots CT/MRI abnormalities in asymptomatic individuals (Johnson et al., 1994)
[15] mhra.gov.uk), contributing to ongoing medication safety monitoring
What It Targets Liraglutide is designed to target: Excess weight and obesity where diet and exercise alone have not led to sufficient, sustained loss. Weightrelated metabolic markers such as elevated blood sugar, prediabetes, insulin resistance, and dyslipidemia. Cravings, portion control challenges, and emotional eating patterns that benefit from strong biological satiety support. Clients motivated to pair medication with structured nutrition, movement, and behavior change for longterm results
The press conference resumed by 1:29 p.m